Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer
Jonat, W., Bachelot, T., Ruhstaller, T., Kuss, I., Reimann, U., Robertson, J. F. R.Volume:
24
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdt216
Date:
October, 2013
File:
PDF, 102 KB
english, 2013